Financial Performance - The company's revenue for Q3 2022 was ¥739,470,118.84, a decrease of 7.61% compared to the same period last year[8] - Net profit attributable to shareholders was ¥39,423,509.54, an increase of 44.23% year-on-year[8] - The net profit excluding non-recurring gains and losses was ¥34,215,800.49, up 102.90% compared to the previous year[8] - Basic earnings per share for the period was ¥0.10, representing a 42.86% increase year-on-year[8] - Total operating revenue for the current period reached ¥2,591,255,169.47, an increase from ¥2,095,524,809.86 in the previous period, representing a growth of approximately 23.7%[35] - Net profit for the period reached 267,089,226.39, a significant increase from 129,756,225.21 in the previous period, representing a growth of approximately 106.5%[38] - Operating profit increased to 338,944,390.07 from 173,269,596.37, reflecting a growth of about 95.7%[38] - Basic earnings per share rose to 0.67 from 0.31, marking an increase of 116.1%[40] - The company reported a total comprehensive income of 267,089,226.39, compared to 134,999,223.02 in the previous period, showing an increase of about 97.6%[40] Assets and Liabilities - Total assets at the end of the reporting period reached ¥5,674,992,548.08, a 7.58% increase from the end of the previous year[8] - The company's total assets increased to ¥5,674,992,548.08 from ¥5,275,153,179.53, reflecting a growth of approximately 7.6%[31] - Current assets totaled ¥2,172,293,095.83, slightly up from ¥2,139,270,567.35, showing a marginal increase of about 1.6%[31] - Non-current assets rose to ¥3,502,699,452.25 from ¥3,135,882,612.18, marking an increase of approximately 11.7%[31] - The total liabilities increased to ¥2,020,062,334.69 from ¥1,835,731,359.76, which is an increase of about 10.1%[34] - The company's equity attributable to shareholders reached ¥3,607,256,546.17, up from ¥3,394,465,354.19, indicating a growth of approximately 6.3%[34] Cash Flow - Cash flow from investing activities showed a net outflow of ¥348,083,859.42, a significant increase of 440.50% compared to the previous period[18] - The company reported a net cash inflow from financing activities of ¥99,140,461.81, a 225.74% increase year-on-year, mainly due to increased bank borrowings[18] - Cash flow from operating activities generated a net amount of 208,227,671.15, down from 232,213,332.77 in the previous period, a decrease of approximately 10.3%[44] - Cash and cash equivalents decreased from ¥981,084,481.31 to ¥889,390,294.90, a decline of about 9.3%[31] - Cash and cash equivalents at the end of the period were 843,296,253.96, down from 964,698,230.63, a decrease of approximately 12.5%[47] - Investment activities resulted in a net cash outflow of -348,083,859.42, compared to -64,400,662.19 in the previous period, reflecting a larger outflow[44] Shareholder Information - The total number of common shareholders at the end of the reporting period is 25,131[19] - The largest shareholder, Zibo Jincheng Industrial Investment Co., Ltd., holds 20.28% of the shares, totaling 78,552,154 shares, with 18,829,799 shares pledged[22] - The second largest shareholder, Industrial and Commercial Bank of China - Guangfa Stable Growth Securities Investment Fund, holds 3.67% of the shares, totaling 14,200,000 shares[22] - The third largest shareholder, National Social Security Fund Combination One, holds 3.59% of the shares, totaling 13,900,000 shares[22] - Shareholder Peng Guohua holds 2.90% of the shares, totaling 11,220,000 shares[22] - Shareholder Zhao Hongfu holds 2.50% of the shares, totaling 9,676,000 shares, with 7,257,000 shares under lock-up[22] - Shareholder Zhao Yeqing holds 1.87% of the shares, totaling 7,227,500 shares, with 5,420,625 shares under lock-up[22] - Shareholder Fu Miaoqing holds 1.58% of the shares, totaling 6,138,332 shares, with 4,626,249 shares under lock-up[22] - The total number of restricted shares at the beginning of the period was 26,115,424, with 32,500 shares released during the period[25] Inventory and Operating Costs - The company's inventory increased by 39.89% to ¥547,416,758.01, attributed to increased stocking and rising raw material prices[12] - Operating costs rose by 43.01% to ¥1,377,627,180.93, primarily due to increased sales volume and raw material costs[15] - Total operating costs amounted to ¥2,283,411,856.62, up from ¥1,971,667,778.59, indicating an increase of about 15.8%[35] - Inventory increased significantly from ¥391,322,226.99 to ¥547,416,758.01, representing a growth of approximately 40%[31] Future Outlook - The company has not disclosed any new strategies or future outlook in the provided documents[26] - The company reported a net profit margin improvement, with net income figures to be detailed in future reports[35]

股票简称：金城医药 股票代码：300233 2022年半年度报告 2022年08月 助 作区均进步 刷字健康主法 山东金城医药集团股份有限公司 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人赵叶青、主管会计工作负责人孙瑞梅及会计机构负责人(会计 主管人员)贺东声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告如涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺， 请投资者注意投资风险。 本报告第三节"管理层讨论与分析"中描述了公司未来经营中可能存在的 风险及应对措施，敬请投资者关注相关内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 3 山东金城医药集团股份有限公司 2022 年半年度报告全文 目录 | --- | --- | |-------------------------------|-------| | | | | 第一节 重要提示、目录和释义 . | ...

Financial Performance - The company's revenue for Q1 2022 was ¥953,062,199.12, representing a 56.50% increase compared to ¥608,977,257.17 in the same period last year[10] - Net profit attributable to shareholders for Q1 2022 was ¥112,478,901.17, a significant increase of 121.18% from ¥50,855,115.49 in the previous year[10] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥109,032,761.00, reflecting a 169.22% increase from ¥40,499,938.16 year-on-year[10] - The company's basic earnings per share for Q1 2022 was ¥0.29, up 123.08% from ¥0.13 in the same quarter last year[10] - The net profit for the current period is 116,066,574.08, a significant increase from 52,846,955.50 in the previous period, representing a growth of approximately 119.8%[48] - The total profit for the current period is 144,236,962.95, compared to 66,708,020.64 in the previous period, indicating an increase of about 116.1%[48] - The operating profit for the current period is 145,165,251.95, up from 68,311,968.89 in the previous period, reflecting a growth of approximately 112.5%[48] - The basic and diluted earnings per share for the current period are both 0.29, compared to 0.13 in the previous period, marking an increase of 123.1%[48] Assets and Liabilities - The total assets at the end of Q1 2022 were ¥5,447,487,026.78, an increase of 3.27% from ¥5,275,153,179.53 at the end of the previous year[12] - Current liabilities totaled ¥1,421,009,274.36, slightly up from ¥1,416,441,979.04, showing a marginal increase of about 0.2%[38] - Non-current liabilities increased to ¥470,766,245.52 from ¥419,289,380.72, representing a growth of approximately 12.3%[38] - The company's cash and cash equivalents at the end of the reporting period amount to ¥933,883,542.38, a decrease from ¥981,084,481.31 at the beginning of the year[32] - The company's total assets rose to ¥5,447,487,026.78, compared to ¥5,275,153,179.53, marking an increase of about 3.3%[41] Cash Flow - The company's cash flow from operating activities showed a net outflow of ¥45,797,444.13, a decline of 741.01% compared to a net inflow of ¥7,144,592.39 in the same period last year[23] - Cash flow from operating activities for the current period is -45,797,444.13, a decline from 7,144,592.39 in the previous period[52] - Cash flow from investing activities shows a net outflow of -89,022,464.34, compared to -104,851,243.41 in the previous period, indicating an improvement[52] - Cash flow from financing activities results in a net inflow of 57,004,584.62, down from 73,393,829.77 in the previous period[55] Shareholder Information - The total number of common shareholders at the end of the reporting period is 23,778[25] - The largest shareholder, Zibo Jincheng Industrial Investment Co., Ltd., holds 20.28% of shares, totaling 78,552,154 shares[25] - The second-largest shareholder, the National Social Security Fund 115 Portfolio, holds 2.84% of shares, totaling 11,000,000 shares[25] - The company has a total of 22,550,274 shares under lock-up agreements, with specific shares set to be released after certain conditions are met[31] Revenue Drivers and Costs - The increase in revenue was primarily driven by the addition of CMO business and growth in sales of cephalosporin products and other pharmaceutical chemicals[16] - Total operating revenue for the current period reached ¥953,062,199.12, a significant increase from ¥608,977,257.17 in the previous period, representing a growth of approximately 56.5%[42] - Total operating costs amounted to ¥810,774,617.57, up from ¥560,141,656.88, indicating an increase of about 44.6%[42] Other Financial Metrics - The company's weighted average return on equity for Q1 2022 was 3.26%, an increase of 1.79% from 1.47% in the same period last year[10] - The company reported a decrease in government subsidies received, with other income dropping by 66.96% to ¥4,948,549.71 compared to the previous year[21] - The company's financial expenses surged by 1,811.90% to ¥4,222,427.29 due to increased exchange losses during the reporting period[21] Research and Development - Research and development expenses for the current period were ¥43,235,054.66, compared to ¥40,366,166.87 in the previous period, reflecting an increase of about 4.6%[42] Inventory and Receivables - Accounts receivable increased to ¥671,368,826.73 from ¥597,999,093.92 at the beginning of the year[32] - The company reported a significant increase in receivables financing, rising to ¥149,282,243.51 from ¥86,000,989.82[32] - Inventory decreased slightly to ¥385,470,403.98 from ¥391,322,226.99, indicating a reduction of approximately 1.9%[35] - The company's cash and cash equivalents were not detailed, but other receivables increased to ¥12,644,912.81 from ¥8,387,712.18, a rise of about 50.8%[35] Future Outlook - The company has not disclosed any new product developments or market expansion strategies in the current report[30] - There are no new mergers or acquisitions reported in the current financial disclosures[30] - The company has not provided specific future performance guidance in the current report[30]

Financial Performance - The company's operating revenue for 2021 was CNY 3,138,454,280.12, representing a 5.96% increase compared to CNY 2,961,935,834.22 in 2020[24] - The net profit attributable to shareholders of the listed company was CNY 107,984,095.16, a significant turnaround from a loss of CNY 488,844,750.60 in 2020, marking a 122.09% increase[24] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 95,263,551.28, compared to a loss of CNY 501,153,411.97 in the previous year, reflecting a 119.01% improvement[24] - The basic earnings per share for 2021 was CNY 0.28, a recovery from a loss of CNY 1.26 per share in 2020, indicating a 122.22% increase[24] - The total assets of the company at the end of 2021 were CNY 5,275,153,179.53, which is a 5.50% increase from CNY 5,000,113,119.10 at the end of 2020[24] - The net assets attributable to shareholders of the listed company were CNY 3,394,465,354.19, showing a slight decrease of 1.27% from CNY 3,437,981,008.87 in 2020[24] - The net cash flow from operating activities was CNY 437,185,450.34, down 19.95% from CNY 546,126,321.60 in the previous year[24] - The weighted average return on net assets was 3.17%, a significant recovery from -13.03% in 2020, reflecting a 16.20% improvement[24] Revenue and Growth - In Q1 2021, the company's operating revenue was approximately CNY 608.98 million, increasing to CNY 1.04 billion in Q4 2021, representing a growth of 71.1% from Q1 to Q4[27] - The revenue from formulation products grew by 14.02% year-on-year, while revenue from biopharmaceuticals and specialty raw materials increased by 28.84%[82] - The revenue from the pharmaceutical manufacturing sector accounted for 100% of total revenue, with a notable contribution from the formulation products segment, which generated CNY 1.23 billion, up 14.02% from the previous year[91] - The company achieved a market share stability in the intermediate products sector, with significant international market growth for biological raw materials such as glutathione and adenosylmethionine, leading to increased sales and market share[86] Product Development and Innovation - The company has not reported any significant new product developments or market expansions in the current report[24] - The company is focusing on expanding its production capabilities in the pharmaceutical intermediates sector, particularly in cephalosporin derivatives, to meet growing global demand[45] - The company is actively pursuing CMO (Contract Manufacturing Organization) business opportunities, which are expected to become a new growth point in the future[45] - The company is developing a range of antibiotics, including Cefaclor dispersible tablets and Clindamycin Phosphate injection, to address various bacterial infections[63] - The company is focusing on expanding its product line with generics in the antibiotic category, including Levofloxacin tablets and Cefuroxime capsules[63] - The company is committed to addressing the needs of patients with antibiotic-resistant infections through its new product developments[63] - The company has established three national-level research platforms and six provincial-level research platforms to enhance its technological capabilities[77] - The company has a total of 39 patents filed in 2021, focusing on various pharmaceutical formulations and methods[70] Market Position and Recognition - The company has established itself as a leading global supplier of cephalosporin intermediates, indicating a strong position in the pharmaceutical supply chain[41] - The company has been recognized as one of the top 100 pharmaceutical manufacturing enterprises in China, highlighting its competitive standing in the industry[43] - The company received recognition as one of the top 500 charitable enterprises in China, enhancing its brand reputation and corporate social responsibility image[88] Challenges and Risks - The company is facing challenges due to rising raw material costs and increased industry competition[82] - The company faces risks from industry policies and market changes, particularly due to new regulations affecting drug pricing and procurement, which may impact sales[162] - The company is exposed to raw material supply and price fluctuation risks, which are influenced by commodity price changes and external factors like natural disasters[166] - The company has a significant accounts receivable balance, which poses a risk of uncollectible debts if clients' financial conditions deteriorate[167] - The company is vulnerable to changes in export tax rebate rates and exchange rate fluctuations, which could affect its export operations and overall performance[168] Strategic Initiatives - The company plans to distribute a cash dividend of CNY 2.00 per 10 shares to all shareholders, based on a total of 383,874,587 shares[6] - The company aims to strengthen its international market presence by enhancing its registration and certification capabilities for raw materials[159] - The company is focusing on integrating internal and external resources to address operational challenges and enhance strategic management systems[160] - The company aims to enhance its operational capabilities through a dynamic strategic management system and a comprehensive CMO/CDMO system[160] Governance and Management - The company has established a robust governance structure to ensure compliance with legal and regulatory requirements, enhancing operational transparency[176] - The company has established a complete and independent financial institution, with a robust accounting system and independent financial decision-making capabilities[189] - The board of directors consists of 8 members, including 3 independent directors, complying with legal and regulatory requirements[179] - The company has implemented a transparent performance evaluation and incentive mechanism for senior management[184] - The company maintains a complete and independent business system, with no interference from the controlling shareholder[185]

证券代码：300233 证券简称：金城医药 公告编号：2021-100 山东金城医药集团股份有限公司 关于参加山东辖区上市公司 2021 年度投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，山东金城医药集团股份有限公司（以下 简称"公司"）将参加由山东证监局、山东上市公司协会联合举办的"山东辖区 上市公司 2021 年度投资者网上集体接待日"活动，现将有关事项公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的网 上平台举行。投资者可以登录"全景·路演天下"网站（http://rs.p5w.net/） 参与本次投资者网上集体接待日活动，互动交流时间为 2021 年 11 月 16 日（星 期二）14:00—16:00。 公司副总裁、董事会秘书朱晓刚和证券事务代表倪艳莉将通过网络在线形式 与投资者进行沟通交流，欢迎广大投资者积极参与。 特此公告。 山东金城医药集团股份有限公司董事会 2021 年 11 月 12 日 ...

Revenue and Profit - The company's revenue for Q3 2021 reached ¥800,352,256.80, representing a 20.63% increase year-over-year[4] - Net profit attributable to shareholders was ¥27,334,089.51, a decrease of 29.08% compared to the same period last year[4] - The net profit excluding non-recurring gains and losses was ¥16,863,703.00, down 52.32% year-over-year[4] - The net profit attributable to shareholders of the parent company decreased by 42.06% to ¥120,339,441.14 compared to ¥207,683,729.50 in the same period last year, primarily due to increased costs from rising raw material prices and declining market prices in the pharmaceutical intermediate sector[2] - Net profit for the current period was ¥129,756,225.21, a decrease of 39.0% from ¥212,645,545.78 in the previous period[33] - The total comprehensive income for the current period was ¥134,999,223.02, down from ¥212,645,545.78, a decrease of 36.5%[36] Cash Flow - Cash flow from operating activities for the year-to-date was ¥232,213,332.77, reflecting a decline of 47.13% compared to the previous year[4] - The net cash flow from operating activities decreased by 47.13% to ¥232,213,332.77, primarily due to increased procurement expenses and other cash payments related to operating activities[2] - The net cash flow from operating activities was $232.21 million, a decrease of 47.2% compared to $439.25 million in the previous period[40] - Cash outflow from operating activities totaled $1.81 billion, up 24.8% from $1.45 billion year-over-year[40] - The net cash flow from investing activities was -$64.40 million, an improvement from -$199.95 million in the previous period[40] Assets and Liabilities - Total assets as of September 30, 2021, amounted to ¥5,148,164,473.55, an increase of 2.96% from the end of the previous year[4] - The company's total assets reached CNY 5,148,164,473.55, up from CNY 5,000,113,119.10 at the end of 2020, indicating an increase of about 2.96%[28] - Total liabilities increased to CNY 1,700,120,234.27 from CNY 1,532,815,590.71, representing a rise of approximately 10.9%[26] - The company's total liabilities amounted to $1.15 billion, remaining stable compared to the previous period[46] - Total liabilities amounted to approximately 1.53 billion, a decrease from 1.60 billion[48] Shareholder Equity - The company's equity attributable to shareholders was ¥3,409,070,935.69, showing a slight decrease of 0.84% from the previous year[4] - The total equity attributable to shareholders decreased to CNY 3,409,070,935.69 from CNY 3,437,981,008.87, reflecting a decline of about 0.84%[29] - Total equity attributable to shareholders reached approximately 3.44 billion, unchanged from the previous period[48] Expenses - Total operating costs amounted to ¥1,971,667,778.59, up from ¥1,695,833,016.81, reflecting a year-over-year increase of 16.2%[30] - Research and development expenses increased to ¥112,080,623.84, up from ¥100,869,291.51, marking a rise of 11.9%[30] - Sales expenses rose to ¥590,656,859.04, compared to ¥522,770,987.36, indicating an increase of 13.0%[30] Other Income and Investments - Other income increased by 143.36% to ¥30,590,759.72, mainly due to government subsidies received amounting to ¥12 million during the reporting period[2] - Investment income rose significantly by 782.46% to ¥1,313,414.69, attributed to increased forward exchange gains[2] - The company reported an investment income of ¥1,313,414.69, recovering from a loss of ¥192,452.61 in the previous period[30] Inventory and Receivables - Accounts receivable decreased by 33.17% to ¥462,866,791.73, attributed to increased sales collections[8] - Inventory increased by 34.31% to ¥381,551,096.60, driven by rising raw material prices and increased stockpiling[8] - The company reported a decrease in accounts receivable to CNY 462,866,791.73 from CNY 692,576,369.97, a significant drop of approximately 33.1%[23] - Inventory levels rose to CNY 381,551,096.60, compared to CNY 284,077,327.28 at the end of 2020, marking an increase of approximately 34.4%[23] Borrowings - Short-term borrowings rose by 44.81% to ¥223,000,000.00, reflecting an increase in bank short-term loans[8] - Short-term borrowings rose to CNY 223,000,000.00 from CNY 154,000,000.00, an increase of approximately 45%[26] - The company’s long-term borrowings stood at $255.39 million, unchanged from the previous period[46] Share Repurchase and Minority Interests - The company repurchased shares amounting to ¥120,013,694.64, reflecting a 63.17% increase in treasury stock[2] - Minority interests increased by 89.79% to ¥9,416,784.07, driven by profit growth in the company's controlling subsidiaries[2] Fair Value Changes and Special Reserves - The company recorded a fair value change income of ¥5,400,300.00, resulting from the impact of exchange rate fluctuations on foreign currency receivables[2] - The company’s special reserves increased by 962.23% to ¥3,308,756.89 due to higher provisions during the reporting period[2] Accounting Standards and Audit Status - The company adopted the revised Accounting Standards for Leases from January 1, 2021, impacting the recognition of lease liabilities[50] - The third quarter report was not audited, indicating preliminary financial data[51]

山东金城医药集团股份有限公司 2021 年半年度报告全文 山东金城医药集团股份有限公司 2021 年半年度报告 2021 年 08 月 1 山东金城医药集团股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人赵叶青、主管会计工作负责人孙瑞梅及会计机构负责人(会计主 管人员)贺东声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中如有涉及未来的计划、发展战略等方面的内容，均不构成本公司 对投资者的实质承诺，投资者及相关人士均应对此保持足够的风险意识，并且 应当理解计划、预测和承诺之间的差异，注意投资风险。 | --- | |---------------------------------------------------------------------------| | | | 公司可能存在产品质量风险、行业政策以及安全环保等相关风险，具体风 | | 险详见第三节管理 ...

Financial Performance - Jincheng Pharmaceutical reported an overall decline in revenue, but its core business of pharmaceutical intermediates, active pharmaceutical ingredients, and finished formulations remained stable[5] - The company's operating revenue for 2020 was ¥2,961,935,834.22, an increase of 5.98% compared to ¥2,794,819,332.70 in 2019[26] - The net profit attributable to shareholders for 2020 was -¥488,844,750.60, a decrease of 340.47% from ¥203,285,186.73 in 2019[26] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥501,153,411.97, down 875.52% from ¥64,621,883.15 in 2019[26] - The net cash flow from operating activities for 2020 was ¥546,126,321.60, a decrease of 5.51% compared to ¥577,983,378.38 in 2019[26] - The total assets at the end of 2020 were ¥5,000,113,119.10, a decrease of 10.59% from ¥5,592,390,582.02 at the end of 2019[26] - The net assets attributable to shareholders at the end of 2020 were ¥3,437,981,008.87, down 15.41% from ¥4,064,167,519.74 at the end of 2019[26] - The company reported a significant decline in basic and diluted earnings per share, both at -¥1.26 for 2020 compared to ¥0.52 in 2019, a decrease of 342.31%[26] - The company’s weighted average return on net assets was -13.03% in 2020, down 18.50% from 5.47% in 2019[26] Impairment and Asset Management - In 2020, Jincheng Pharmaceutical's subsidiary, Jincheng Tail, experienced a significant decline in sales due to industry policies and the pandemic, leading to a substantial goodwill impairment of CNY 769.9794 million[5] - The company recorded an asset impairment provision totaling CNY 769.9794 million, impacting net profit, total assets, and net assets for 2020[7] - The company’s goodwill decreased by 741.7295 million yuan, with a year-end balance of 0, due to impairment provisions for subsidiaries[46] - The company reported no goodwill on the balance sheet due to impairment provisions made during the reporting period[106] Research and Development - Jincheng Pharmaceutical has been focusing on integrating intermediates, active pharmaceutical ingredients, and formulations to enhance its core competitiveness[7] - The company plans to accelerate product research and development and new project construction to create new economic growth points[7] - The company established the Jincheng Pharmaceutical Research Institute to unify R&D innovation platforms and enhance product development capabilities[54] - The company made significant progress in R&D, including breakthroughs in nicotine, 4AA, and cephalosporin technology, marking a new phase in the transformation of its pharmaceutical and chemical industry[55] - The company has a strong pipeline of new products, with multiple patents pending approval for innovative drug formulations and synthesis methods[62] - The company is actively pursuing technological advancements in drug development, as evidenced by its numerous patent applications in innovative synthesis methods[62] Market and Sales Performance - The company’s sales model combines commercial distribution with professional academic promotion, while its international market strategy focuses on self-export and domestic trade company support[44] - The company focused on market expansion, achieving substantial growth in the North American market for glutathione products[55] - Domestic sales reached ¥2,250,562,875.12, which is 75.98% of total sales, showing an 11.36% increase from ¥2,020,960,533.47[76] - International sales were ¥711,372,959.10, accounting for 24.02% of total sales, reflecting an 8.07% decrease from ¥773,858,799.23[76] Strategic Initiatives and Investments - The company established Shandong Jincheng Kunlun Pharmaceutical Co., Ltd. and Shandong Jincheng Pharmaceutical Research Institute Co., Ltd. to strengthen the raw material drug industry platform[39] - The company aims to create a full industry chain from pharmaceutical intermediates to raw materials and then to terminal preparations[39] - The company has committed to investing CNY 6.48 million in the 50 tons/year 7-AVCA industrialization project, which has been redirected to the glutathione project[140] - The company has reported a significant focus on expanding its product lines and enhancing production capabilities through strategic investments[126] Operational Efficiency and Management - The company implemented a comprehensive risk management system and improved internal control measures, earning recognition as a national advanced unit in internal auditing for 2017-2019[56] - The company launched the intelligent scheduling center and smart warehouse, enhancing operational efficiency in logistics and inventory management[56] - The company has effectively controlled project costs, resulting in a remaining balance of CNY 2.47 million from the AE-active ester new process industrialization project[158] Corporate Social Responsibility - The company actively participated in pandemic relief efforts, donating cash and medical supplies to affected areas, earning recognition as a "Demonstration Enterprise for Responsibility in Pandemic Response"[59] Financial Health and Liabilities - The company reported no financial liabilities at the end of the reporting period, maintaining a clean balance sheet[107] - The cash and cash equivalents decreased by ¥102,373,046.61, marking a 138.63% decline compared to the previous year[101] Future Outlook - The pharmaceutical industry in China is expected to maintain stable growth, supported by government policies, rising disposable income, and an aging population[8] - The company is committed to expanding its market presence and enhancing brand influence through various strategic initiatives[59]

Financial Performance - The company's operating revenue for Q1 2021 was ¥608,977,257.17, a decrease of 6.41% compared to ¥650,685,404.33 in the same period last year[8]. - Net profit attributable to shareholders was ¥50,855,115.49, down 49.66% from ¥101,030,988.13 year-on-year[8]. - The net profit after deducting non-recurring gains and losses was ¥40,499,938.16, a decline of 59.32% from ¥99,564,127.60 in the previous year[8]. - Basic and diluted earnings per share were both ¥0.13, down 50.00% from ¥0.26 year-on-year[8]. - The weighted average return on net assets was 1.47%, a decrease of 0.98% from 2.45% in the previous year[8]. - The company reported a revenue of 608.98 million yuan, a year-on-year decrease of 6.41%[24]. - The net profit attributable to shareholders was 50.86 million yuan, down 49.66% year-on-year, primarily due to weakened demand from downstream customers in the pharmaceutical intermediate sector affected by the pandemic[24]. - The company reported a net profit of ¥584,151,634.40, up from ¥533,296,518.91, indicating a growth of approximately 9.56% in retained earnings[61]. - Total comprehensive income amounted to CNY 52,846,955.50, a decrease from CNY 101,584,922.00 in the previous period[77]. Cash Flow and Liquidity - The net cash flow from operating activities was ¥7,144,592.39, a significant drop of 91.33% compared to ¥82,376,320.62 in the same period last year[8]. - Cash and cash equivalents increased to ¥1,079,948,808.21 from ¥1,074,969,550.07, showing a slight growth[52]. - The total cash and cash equivalents at the end of the period amounted to 851,540,955.63, down from 1,001,465,378.99 in the previous period, reflecting a decrease of approximately 14.94%[91]. - The net cash flow from operating activities was -10,352,951.45, slightly improved from -10,817,347.95 in the previous period[92]. - Cash inflows from operating activities totaled 4,821,000.56, an increase from 4,295,191.39 in the previous period[92]. - The net cash flow from financing activities was 73,393,829.77, compared to a negative cash flow of -19,585,031.96 in the previous period, indicating a significant improvement[91]. - The cash flow from financing activities showed a net inflow of 326,770,625.00, compared to 85,771,719.99 in the previous period, marking a substantial increase[95]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,056,843,328.48, an increase of 1.13% from ¥5,000,113,119.10 at the end of the previous year[8]. - Total current assets amounted to ¥2,186,571,091.82, a decrease of 1.58% from ¥2,221,848,961.83 on December 31, 2020[52]. - Total liabilities slightly increased to ¥1,535,255,546.80 from ¥1,532,815,590.71, showing a marginal rise[58]. - The total equity attributable to shareholders rose to ¥3,490,279,422.15 from ¥3,437,981,008.87, an increase of about 1.52%[61]. - Total liabilities reached CNY 203,529,431.12, with current liabilities at CNY 155,732,903.31 and non-current liabilities at CNY 47,796,527.81[103]. Expenses - Research and development expenses rose by 70.24% to RMB 40.37 million, driven by increased investment in R&D projects[21]. - Sales expenses increased by 37.70% to RMB 161.34 million, attributed to enhanced market and brand promotion efforts[21]. - Management expenses rose to CNY 10,823,033.91 from CNY 7,559,057.10 in the previous period, indicating higher administrative costs[78]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,477[12]. - The largest shareholder, Zibo Jincheng Investment Co., Ltd., held 20.13% of the shares, totaling 78,552,154 shares[13]. Market Conditions - The ongoing pandemic continues to pose significant uncertainty for the company's export business, particularly affecting sales to India[24]. - The company is closely monitoring the pandemic's developments and their impact on export operations[24]. Other Financial Metrics - The company's tax payable decreased by 69.84% to RMB 14.63 million, primarily due to a decline in VAT and corporate income tax[21]. - The company's inventory shares decreased by 45.61% to RMB 40.01 million, resulting from the cancellation of repurchased shares[21]. - The company reported a 262.41% increase in other income to RMB 14.98 million, largely due to government subsidies received[21]. - The company's investment income decreased by 133.42% to a loss of RMB 221,822.67, attributed to increased losses from external investments[21].

山东金城医药集团股份有限公司 2020 年第三季度报告全文 山东金城医药集团股份有限公司 2020 年第三季度报告 2020 年 10 月 1 山东金城医药集团股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人赵叶青、主管会计工作负责人孙瑞梅及会计机构负责人(会计主 管人员)贺东声明：保证季度报告中财务报表的真实、准确、完整。 2 山东金城医药集团股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |-----------------------------------------------------|-----------------------------------|-------------------------|--------- ...